At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
RO7234292 (RG6042)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)
In Brief
A Phase 2 clinical trial evaluating RO7234292 (RG6042) for Huntington's Disease. Completed, enrolled 46 participants across 9 sites in 3 countries.
Detailed Summary
This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7234292 administered intrathecally to adult patients with Huntington's Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington's Disease
CountriesCanada, Germany, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartJan 2018
Primary CompletionOct 2019
TodayJul 2026
First PostedNov 14, 2017
Enrollment StartJan 2, 2018
Primary CompletionOct 8, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.6 years ago
Interventions
RO7234292 (RG6042)drug
Intrathecal injection